OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Child and Adolescent Psychopharmacology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
A Retrospective Study of Long-Term Associations of Behavioral Intervention Combined with Medications in Young Children with Attention-Deficit/Hyperactivity Disorder	31
Efficacy of Centanafadine for Executive Functioning and Learning Problems in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder	28
Pharmacological Treatment of Tourette Disorder in Children	23
Description, Implementation, and Efficacy of the Comprehensive Behavioral Intervention for Tics as First-Line Treatment for Tourette and Other Tic Disorders	23
Letter: Mirtazapine-Associated Hyperkinetic Movements in a 17-Year-Old with Autism Spectrum Disorder and Chronic Catatonia: A Case Report	19
Letter: Fluoxetine for Behavioral Problems in an 8-Year-Old with Mucopolysaccharidosis IIIA	19
Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis	19
Reducing Psychotropic Medication Use in Foster-Care Children with a Personalized Medication Review	19
Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications	17
Acknowledgment of Reviewers 2023	16
Letter: Preliminary Observations from a Randomized, Open-Label Trial of Loperamide as Adjunctive Treatment for Social Deficits in Autism Spectrum Disorder	15
Incidence of Neuroleptic Malignant Syndrome During Antipsychotic Treatment in Children and Youth: A National Cohort Study	15
Navigating Pharmacological Treatment in an Adolescent with New Onset Psychosis: Clinical, Pharmacological, and Cultural Challenges	14
From the Editor-in-Chief's Desk: Reflecting on Our Past and Future	13
A Double-Blind Placebo-Controlled Pilot Study of Topiramate in Manic Adolescents Treated with Olanzapine	13
Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES)	12
Short-Term Vision-Related Ocular Side Effects of Treatment with Dexmethylphenidate for Attention-Deficit/Hyperactivity Disorder	11
A Mobile Application Adjunct to Augment Cognitive–Behavioral Group Therapy for Adolescents with Social Anxiety: Feasibility and Acceptability Results from the Wiring Adolescents with Social Anxiety vi	11
Letter to the Editor: Transition to In-Person School After Remote Learning—Mental Health Concerns in Youth with Developmental Disabilities	10
Pharmacological Interventions for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Tourette Disorder: A Systematic Review and Network Meta-Analysis	10
Psychotropic Medication Prescribing: Youth in Foster Care Compared with Other Medicaid Enrollees	10
From the Editor's Desk: Progress and Challenges for Psychiatric Phenotypes in Youth	10
Response to Plöderl et al. re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder”	10
Letter: Integrating Insights on Ketamine Efficacy and the Risk for Polydrug Use in Adolescents with Depression	9
Determining Clinically Meaningful Improvement in Children and Adolescents with Tourette Syndrome Receiving Pharmacotherapy	9

From the Editor-in-Chief’s Desk: Long-Acting Injectable Antipsychotics	9
From the Editor-in-Chief’s Desk: Maximizing Adherence, Digital Platforms, and Early Response for Precision Pediatric Psychopharmacology	9
Reported Side or Adverse Effects Associated with Medication Nonadherence Among Adolescents and Young Adults with Attention-Deficit/Hyperactivity Disorder	9
Placebo Response on Attention-Deficit/Hyperactivity Disorder Ratings: Application to Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder 3-Month Outcomes	9
Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor	9
Letter: Eye Movement Desensitization Reprocessing and Transcranial Magnetic Stimulation in an Adolescent with Comorbid Major Depression Disorder and Posttraumatic Stress Dis	9
Letter: Improving Outcomes in Level 3 Autism after Treating Co-Occurring ADHD	9
Letter: Low CK, High Suspicion: A Case of Atypical Neuroleptic Malignant Syndrome in a Pediatric Post-Transplant Patient	8
The Curious Case of Therapist Self-Disclosure During Pharmacotherapy Visits in an Autism Center	8
Letter: Catatonia Treatment in Down Syndrome Regressive Disorder with Repeated Vineland Assessment: A Case Report	8
Letter to the Editor: Suicide Risk Screening Practices in Youth with Developmental Disabilities	8
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study	7
Psychiatric Polygenic Risk Scores and Week-by-Week Symptomatic Status in Youth with Bipolar Disorder: An Exploratory Study	7
Can Neurocognitive Outcomes Assist Measurement-Based Care for Children with Attention-Deficit/Hyperactivity Disorder? A Systematic Review and Meta-Analyses of the Relationships Among the Changes in Ne	7
Erratum to: Assessing the Predictive Utility of Quantitative Electroencephalography Coherence in Adolescent Major Depressive Disorder: A Machine Learning Approach	7
Pediatric Neuropsychiatric Syndromes: Updates on COVID-19 Infection and Vaccination	7
A Counting Stroop Functional Magnetic Resonance Imaging Study on the Effects of ORADUR-Methylphenidate in Drug-Naive Children with Attention-Deficit/Hyperactivity Disorder	7
Association of Coexisting Conditions, Attention-Deficit/Hyperactivity Disorder Medication Choice, and Likelihood of Improvement in Preschool-Age Children: A Developmental Behavioral Pediatrics Researc	7
Changes in Psychiatric Medication Use During the COVID-19 Pandemic in a Pediatric Long-Term Care Facility	7
Ketamine and Transcranial Magnetic Stimulation in an Adolescent with Treatment-Resistant Depression	7
Rising Prevalence of Pediatric Catatonia Presenting to Inpatient Care: A Retrospective Analysis	6
Association Between Single-Dose and Longer Term Clinical Response to Stimulants in Attention-Deficit/Hyperactivity Disorder: A Systematic Review of Randomized Controlled Trials	6
Correction to: A Predictive Biomarker Model Using Quantitative Electroencephalography in Adolescent Major Depressive Disorder, by McVoy, et al. J Chil	6
Bowel and Bladder Dysfunction Is Associated with Psychiatric Comorbidities and Functional Impairment in Pediatric Obsessive-Compulsive Disorder	6
From the Editor-in-Chief's Desk	6
Letter: Beyond Crisis, Prolonged Effectiveness of Ketamine in Adolescents with Treatment-Refractory Depression	6
Long-Acting Injectable Antipsychotics in Adolescents with Bipolar Disorder	6
Pain in Tourette Syndrome: A Comprehensive Review	6
Vascular Endothelial Growth Factor Polymorphism rs699947 Is Associated with Neurostructural Phenotypes in Youth with Bipolar Disorder	6
Long-Term Improvement and Safety of Aripiprazole for Irritability and Adaptive Function in Asian Children and Adolescents with Autistic Disorder: A 52-Week, Multinational, Multicenter, Open-Label Stud	6
Letter: Collaborating with Applied Behavior Analysis Teams to Optimize Telehealth Pharmacologic Management of Catatonia in Nonverbal Youth with Autism Spectrum Disorder	6
Examining Whether Genetic Variants Moderate the Skeletal Effects of Selective Serotonin Reuptake Inhibitors in Older Adolescents and Young Adults	6
The Safety and Clinical Effects of Amisulpride in Children and Adolescents with Psychiatric Disorders: A Case Series	6
Response to Chadi A. Calarge re: “Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)”	6
Rational Psychopharmacological and Psychotherapeutic Treatment of a 14-Year-Old Female with Functional Neurological Symptoms Disorder and Depression	6
Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia	6
Response to Letter: “Refining Atomoxetine Research for Adolescent NSSI”	6
Access to Care in Pediatric Acute-Onset Neuropsychiatric Syndrome: A Survey of Families’ Journeys to and Experiences with Intravenous Immunoglobulin Treatment	5
Prevalence and Factors Affecting the Use of Antipsychotics and Antipsychotic Polypharmacy in a Child and Adolescent Psychiatry Inpatient Service	5
A Neurodevelopmental Model of Social Threat Sensitivity as a Mechanism Linking Fearful Temperament, Social Anxiety, and Depression in Youth	5
Clonazepam Treatment of Adolescent Catatonia in A Setting of Lorazepam-Related Hypotension	5
Rapids Crisis Service for Children and Adolescents 2019–2024: 6-Year Changes in Crisis Service at Lambeth Children and Adolescent Mental Health Services in London, United Kingdom	5
From the Editor-in-Chief’s Desk: Gratitude for Mentors and Colleagues	5
From the Editor-in-Chief's Desk: Advances in Patient-Centered Treatment for Attention-Deficit/Hyperactivity Disorder	5
Sex-Specific Effects of Relative Fat Mass on Attention-Deficit/Hyperactivity Disorder: Insights from the 1999–2004 National Health and Nutrition Examination Survey	5
Long-Acting Injectable Antipsychotics and Time to Readmission in Early Psychosis	5
Multivariable Prediction Modeling of Antidepressant Initiation in Unipolar Depressed Adolescents: A Secondary Analysis of the IMPACT Trial	5
Comparing Symptoms of Major Depression in Youth with Confirmed Versus Suspected Bipolar Disorder	5
Correction to: A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder, by Strawn et al.	5
Adherence to Clinical Guidelines for Dose Finding and Monitoring Methylphenidate Use: A Medical Record Audit in Child and Adolescent Mental Health Care and Pediatric Settings	5

Letter: Fentanyl Test Strips in Adolescent Care: Considerations for Safe Implementation	5
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Journal of Child and Adolescent Psychopharmacology	5
Efficacy of Preventing Relapse Evaluated by a Multicenter Randomized Double-Blind Placebo-Controlled Withdrawal Study of Escitalopram in Japanese Adolescents with Major Depressive Disorder	5
Factors Associated with Symptom Persistence in PANS: Part II—Presenting Features, Medical Comorbidities, and IVIG Treatment History	5
Stimulant Patterns, Alone or with Other Psychotropic Classes, in Medicaid-Insured Youth Continuously Enrolled for 3–8 Years	5
Comorbidities in School-Age Children and Adolescents with Autism in an Ethnically Diverse Population: Brief Report	4
Clinicians' Adherence to Guidelines When Initiating Methylphenidate Treatment	4
From the Editor-in-Chief's Desk	4
Results from a Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Trial of Lovastatin or Minocycline in Fragile X Syndrome	4
Pharmacogenetics and Oxcarbazepine in Children and Adolescents: Beyond HLA-B *15:02	4
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-	4
Electronically Monitored Antidepressant Adherence in Adolescents with Anxiety Disorders: A Pilot Study	4
The Role of Maladaptive Behaviors and Adjustment Disorders in Linking Separation Anxiety to Depression in Primary School Students	4
From the Editor-in-Chief's Desk	4
Correction to: The Importance of Second-Generation Antipsychotic-Related Weight Gain and Adherence Barriers in Youth with Bipolar Disorders: Patient, Parent, and Provider Pe	4
A Discrepancy in the Reports on Life Events Between Parents and Their Depressed Children Is Associated with Lower Responsiveness to SSRI Treatment	4
SSRI-Induced Galactorrhea in Adolescents	4
Letter: Seventeen-Year-Old Develops Neuroleptic Malignant Syndrome after Brief Low-Dose Exposure to Aripiprazole: A Case Report	4
A Scoping Review of the Intersectionality of Autism and Intellectual and Developmental Disability with Social Inequity on Diagnosis and Treatment of Youth	4
Pilot Trial of Adjunctive Curcumin for Treatment-Resistant Bipolar Depression in Youth: Focus on Inflammation and Oxidative Stress	4
From the Editor-in-Chief's Desk	4
Letter: Considerations for Refining Research of Atomoxetine in Adolescents with Nonsuicidal Self-Injury	4
Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate	4
Trajectories and Predictors for the Development of Clinically Significant Weight Gain in Children and Adolescents Prescribed Second-Generation Antipsychotics	4
Prevalence and Correlates of Eating Disorder Symptoms in Adolescents with Bipolar I Disorder	4
The Psychosocial Environment as Therapeutic Context: Family-Centered Approaches to Adolescent Psychedelic Research	4
From the Editor-in-Chief’s Desk: Special Issue on the Psychopharmacology of Neurodevelopmental Disorders	4
Letter: Food and Drug Administration Clearance of Transcranial Magnetic Stimulation for Adolescent Depression in the Absence of Data Supporting Efficacy	4